Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin versus gliclazide for new-onset diabetes after renal transplant
ACTRN12613000224729Phase 4Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in post-transplantation diabetes mellitus (PTDM) comparing Vildagliptin with Gliclazide modified release (2 arms). Primary endpoint: Hypoglycaemic events. Planned start Mar 2013; status: not yet recruiting.
02
Drugs
vildagliptingliclazide
03
Conditions
post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on ACTRN12613000224729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000224729.